 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...253254255256257258259260261262263...266267» |
- | Selectikine (EMD 521873) / EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: EMR 062235-005: MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma (clinicaltrials.gov) - Apr 16, 2015
P2, N=12, Active, not recruiting, Sponsor: EMD Serono
Recruiting --> Active, not recruiting | N=86 --> 12 | Trial primary completion date: Jan 2016 --> Feb 2015
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Apr 14, 2015
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=86 --> 12 | Trial primary completion date: Jan 2016 --> Feb 2015 Trial primary completion date: Apr 2015 --> Apr 2016
- | PD(L)-1 Biomarker, IO biomarker: DREAMseq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (clinicaltrials.gov) - Apr 14, 2015
P3, N=300, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Apr 2016 Initiation date: Nov 2014 --> Apr 2015
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change: CheckMate 143: A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (clinicaltrials.gov) - Apr 14, 2015
P3, N=440, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Nov 2014 --> Apr 2015 N=260 --> 440
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Combination therapy, Metastases: Ipilimumab and Lenalidomide in Advanced Cancer (clinicaltrials.gov) - Apr 14, 2015
P1, N=101, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=260 --> 440 Trial primary completion date: Mar 2016 --> Mar 2017
- || Yervoy (ipilimumab) / BMS
Trial primary completion date: Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=57, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Sep 2015 --> Sep 2016
- |||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date: Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (clinicaltrials.gov) - Apr 14, 2015
P3, N=1125, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Nov 2015 --> Mar 2015
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker: Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 14, 2015
P2, N=54, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2015 --> Mar 2015 Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Apr 2015 | Trial primary completion date: Aug 2017 --> Apr 2017
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker, IO biomarker: CheckMate 238: Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (clinicaltrials.gov) - Apr 14, 2015
P3, N=800, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Apr 2015 | Trial primary completion date: Aug 2017 --> Apr 2017 Not yet recruiting --> Recruiting
- ||||| varlilumab (CDX 1127) / Celldex, rasdegafusp alfa (CDX-1401) / Celldex
New P2 trial, Combination therapy, Metastases: A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - Apr 10, 2015
P2, N=100, Recruiting, Sponsor: Celldex Therapeutics
- ||| Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Ipi4: A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (clinicaltrials.gov) - Apr 10, 2015
P4, N=150, Active, not recruiting, Sponsor: Oslo University Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=100 --> 150 | Trial primary completion date: Dec 2015 --> Dec 2018
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: CheckMate 040: An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (clinicaltrials.gov) - Apr 9, 2015
P1, N=405, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=100 --> 150 | Trial primary completion date: Dec 2015 --> Dec 2018 N=250 --> 405 | Trial primary completion date: May 2017 --> Jul 2018
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, PD(L)-1 Biomarker: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 6, 2015
P1, N=42, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Apr 6, 2015
P1/2, N=204, Recruiting, Sponsor: National Cancer Institute (NCI)
N=250 --> 405 | Trial primary completion date: May 2017 --> Jul 2018 Suspended --> Recruiting
- Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Doxycycline, Temozolomide and Ipilimumab in Melanoma (clinicaltrials.gov) - Apr 6, 2015
P1/2, N=58, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting Recruiting --> Active, not recruiting
- ||| enoblituzumab (MGA271) / MacroGenics
Enrollment open, Combination therapy: Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer (clinicaltrials.gov) - Apr 5, 2015
P1, N=84, Recruiting, Sponsor: MacroGenics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Adverse events, Metastases: Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan (clinicaltrials.gov) - Apr 2, 2015
P=N/A, N=25, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | Vesanoid (tretinoin) / Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
New P2 trial, Metastases: Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (clinicaltrials.gov) - Apr 2, 2015
P2, N=60, Not yet recruiting, Sponsor: University of Colorado, Denver
- Yervoy (ipilimumab) / BMS
New P1 trial, Checkpoint inhibition, IO biomarker, Metastases: Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma (clinicaltrials.gov) - Apr 2, 2015
P1, N=21, Recruiting, Sponsor: Radiotherapie
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker: Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 25, 2015
P2, N=54, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Enrollment open, Surgery, Metastases: High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 20, 2015
P2, N=82, Recruiting, Sponsor: Rutgers, The State University of New Jersey
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial, PD(L)-1 Biomarker, IO biomarker: CheckMate 238: Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (clinicaltrials.gov) - Mar 17, 2015
P3, N=800, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Yervoy (ipilimumab) / Ono Pharma, BMS
Phase classification: Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma (clinicaltrials.gov) - Mar 12, 2015
P1, N=44, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Phase classification: P1/2 --> P1
- | Yervoy (ipilimumab) / BMS
New P1/2 trial: Mel62; 6PAC: A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (clinicaltrials.gov) - Mar 11, 2015
P1/2, N=51, Not yet recruiting, Sponsor: Craig L Slingluff, Jr
- ||| enoblituzumab (MGA271) / MacroGenics
New P1 trial, Combination therapy: Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer (clinicaltrials.gov) - Mar 7, 2015
P1, N=84, Not yet recruiting, Sponsor: MacroGenics
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date, Monotherapy: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (clinicaltrials.gov) - Mar 5, 2015
P3, N=1070, Recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P1/2 --> P1 Initiation date: Jan 2014 --> Oct 2014
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Enrollment open, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 038: PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (clinicaltrials.gov) - Mar 2, 2015
P1, N=160, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2014 --> Oct 2014 Active, not recruiting --> Recruiting
- Biomarker, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 27, 2015
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Trial primary completion date: Feb 2015 --> Jun 2016
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker, IO biomarker: ABC: Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (clinicaltrials.gov) - Feb 27, 2015
P2, N=75, Recruiting, Sponsor: Melanoma Institute Australia
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Enrollment closed, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 038: PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (clinicaltrials.gov) - Feb 27, 2015
P1, N=160, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Feb 2015 --> Jun 2016 Not yet recruiting --> Active, not recruiting
- Cavatak (gebasaxturev) / Merck (MSD)
Enrollment open, Metastases: Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (clinicaltrials.gov) - Feb 26, 2015
P1, N=26, Recruiting, Sponsor: Viralytics
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Trial initiation date, Trial primary completion date, Adverse events: Ipilimumab 12-month Intensive Pharmacovigilance Protocol (clinicaltrials.gov) - Feb 23, 2015
P=N/A, N=30, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Dec 2012 | Trial primary completion date: Jan 2015 --> Oct 2015
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial primary completion date, Monotherapy: CheckMate 204: An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (clinicaltrials.gov) - Feb 20, 2015
P2, N=148, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Dec 2012 | Trial primary completion date: Jan 2015 --> Oct 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2017 --> Mar 2018
- |||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Metastases: Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin (clinicaltrials.gov) - Feb 19, 2015
P3, N=920, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2017 --> Mar 2018 Trial primary completion date: Oct 2015 --> Jun 2015
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Feb 19, 2015
P1/2, N=204, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2015 --> Jun 2015 N=160 --> 204 | Not yet recruiting --> Suspended
- Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Feb 19, 2015
P1, N=23, Recruiting, Sponsor: National Cancer Institute (NCI)
N=160 --> 204 | Not yet recruiting --> Suspended Suspended --> Recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Monotherapy, PD(L)-1 Biomarker: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (clinicaltrials.gov) - Feb 9, 2015
P1, N=412, Recruiting, Sponsor: Bristol-Myers Squibb
Suspended --> Recruiting Trial primary completion date: Nov 2016 --> Jul 2017
- Trial initiation date, Trial primary completion date: Adoptive Therapy Using Antigen-Specific CD4 T-Cells (clinicaltrials.gov) - Feb 9, 2015
P1, N=12, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2016 --> Jul 2017 Initiation date: Sep 2014 --> Jul 2015 | Trial primary completion date: Sep 2017 --> Jul 2018
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date, Monotherapy: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (clinicaltrials.gov) - Feb 6, 2015
P3, N=1070, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Sep 2014 --> Jul 2015 | Trial primary completion date: Sep 2017 --> Jul 2018 Initiation date: Oct 2014 --> Jan 2014
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial: Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs (clinicaltrials.gov) - Jan 30, 2015
P2, N=35, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma (clinicaltrials.gov) - Jan 28, 2015
P2, N=100, Recruiting, Sponsor: New York University School of Medicine
Initiation date: Oct 2014 --> Jan 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: CheckMate 040: An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (clinicaltrials.gov) - Jan 28, 2015
P1, N=245, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2014 --> Dec 2015 N=90 --> 245 | Trial primary completion date: May 2016 --> May 2017
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Jan 26, 2015
P2, N=20, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=90 --> 245 | Trial primary completion date: May 2016 --> May 2017 Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: Apr 2019 --> Jan 2019
- || lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor (clinicaltrials.gov) - Jan 26, 2015
P1, N=125, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: Apr 2019 --> Jan 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Mar 2016
- Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Monotherapy, Metastases: Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (clinicaltrials.gov) - Jan 22, 2015
P1, N=30, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Mar 2016 Trial primary completion date: Apr 2015 --> Jun 2016
- Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Jan 22, 2015
P1, N=27, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Jun 2016 Recruiting --> Suspended
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Combination therapy, Metastases: NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Jan 20, 2015
P1, N=27, Recruiting, Sponsor: Ludwig Institute for Cancer Research
Recruiting --> Suspended Trial primary completion date: Nov 2014 --> May 2016
- Avastin (bevacizumab) / Roche, Yervoy (ipilimumab) / BMS
Trial primary completion date, Surgery, Metastases: Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 15, 2015
P2, N=176, Recruiting, Sponsor: Academic and Community Cancer Research United
Trial primary completion date: Nov 2014 --> May 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Metastases: Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity (clinicaltrials.gov) - Jan 15, 2015
P2, N=39, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Feb 2015 --> Feb 2016
- | Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2/3 trial, PD(L)-1 Biomarker: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Jan 15, 2015
P2/3, N=400, Not yet recruiting, Sponsor: National Cancer Institute (NCI)